Pulse Biosciences
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 56
- Market Cap
- -
- Introduction
Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments uses a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Hayward, CA.
Clinical Trials
14
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials
NS-PFA Catheter Ablation of Paroxysmal and Persistent Atrial Fibrillation With the Pulse Biosciences CellFX System
- Conditions
- Atrial Fibrillation ParoxysmalCardiac AblationCardiac ArrhythmiaAtrial Fibrillation, Persistent
- First Posted Date
- 2025-06-12
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- Pulse Biosciences, Inc.
- Target Recruit Count
- 375
- Registration Number
- NCT07018596
- Locations
- 🇧🇪
Clinic Electrophysiology, Heart Center Hasselt, Jessa Hospital, Hasselt, Belgium
🇨🇿Na Homolce Hospital, Prague, Roentgenova, Czechia
CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation
- Conditions
- Atrial FibrillationMaze ProcedureAFAblation
- First Posted Date
- 2025-05-06
- Last Posted Date
- 2025-06-08
- Lead Sponsor
- Pulse Biosciences, Inc.
- Target Recruit Count
- 135
- Registration Number
- NCT06959121
Evaluation of the CellFX® Nano-Pulsed Field Ablation (PFA) 360 Catheter Endocardial Ablation System for the Treatment of Atrial Fibrillation
- Conditions
- Atrial Fibrillation ParoxysmalCardiac AblationCardiac Arrhythmia
- First Posted Date
- 2024-11-20
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Pulse Biosciences, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT06696170
- Locations
- 🇨🇿
Na Homolce Hospital, Prague, Roentgenova, Czechia
CellFX® nsPFA™ Cardiac Surgery System to Treat Atrial Fibrillation
- Conditions
- SurgeryAtrial Fibrillation
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Pulse Biosciences, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06355063
- Locations
- 🇳🇱
Academic Medical Center, Amsterdam, Netherlands
🇳🇱Maastricht University Medical Center+ (MUMC+), Maastricht, Netherlands
🇳🇱St. Antonius Hospital, Nieuwegein, Netherlands
CellFX ® Percutaneous Electrode (PE) Treatment of Symptomatic Benign Thyroid Nodules
- Conditions
- Thyroid Nodule (Benign)
- First Posted Date
- 2023-11-03
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Pulse Biosciences, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06117085
- Locations
- 🇮🇹
Ospedale del Mare | ASLNA1 Centro, Naples, Italy
- Prev
- 1
- 2
- 3
- Next